Search
Artelo Biosciences Inc
ARTLAdd to Watchlist
1.840USD
-0.500-21.37%
Close 05/15, 16:00（ET）Quotes delayed by 15 min
4.29MMarket Cap
LossP/E TTM
More Details of Artelo Biosciences Inc Company
Artelo Biosciences, Inc. is a clinical-stage pharmaceutical company dedicated to the development and commercialization of therapeutics that modulate lipid-signaling pathways. The Company is advancing a portfolio of broadly applicable product candidates designed to address significant unmet needs in multiple diseases and conditions, including anorexia, cancer, anxiety, dermatologic conditions, pain, and inflammation. Its pipeline products include ART26.12, ART27.13 and ART12.11. ART26.12, its Fatty Acid Binding Protein 5 (FABP5) inhibitor, is being developed as a novel, peripherally acting, non-opioid, non-steroidal analgesic. The Cancer Appetite Recovery Study (CAReS) is a Phase 1/2 randomized, placebo-controlled trial of its clinical program, ART27.13, in patients with cancer anorexia and weight loss. ART12.11, the Company's novel solid-state cannabidiol composition co-formed with tetramethylpyrazine, is targeted for development in anxiety disorders and rare/orphan diseases.
Artelo Biosciences Inc Info
Ticker SymbolARTL
Company nameArtelo Biosciences Inc
IPO dateOct 13, 2015
CEOGorgas (Gregory D)
Number of employees6
Security typeOrdinary Share
Fiscal year-endOct 13
Address505 Lomas Santa Fe, Suite 160
CitySOLANA BEACH
Stock exchangeNASDAQ OMX - NASDAQ BASIC
CountryUnited States of America
Postal code92075
Phone18589257049
Websitehttps://artelobio.com/
Ticker SymbolARTL
IPO dateOct 13, 2015
CEOGorgas (Gregory D)
Company Executives of Artelo Biosciences Inc
Name
Name/Position
Position
Shareholding
Change
Ms. Connie L. Matsui
Ms. Connie L. Matsui
Independent Chairperson of the Board
Independent Chairperson of the Board
11.74K
+98.21%
Mr. Gregory D. (Greg) Gorgas
Mr. Gregory D. (Greg) Gorgas
President, Chief Executive Officer, Secretary, Director
President, Chief Executive Officer, Secretary, Director
4.02K
+71.71%
Mr. Steven (Steve) Kelly
Mr. Steven (Steve) Kelly
Independent Director
Independent Director
47.00
--
Dr. Douglas Blayney, M.D.
Dr. Douglas Blayney, M.D.
Independent Director
Independent Director
--
--
Dr. R. Martin Emanuele, Ph.D.
Dr. R. Martin Emanuele, Ph.D.
Independent Director
Independent Director
--
--
Dr. Gregory R. Reyes, M.D., Ph.D.
Dr. Gregory R. Reyes, M.D., Ph.D.
Independent Director
Independent Director
--
--
Ms. Tamara A. (Seymour) Favorito, CPA
Ms. Tamara A. (Seymour) Favorito, CPA
Independent Director
Independent Director
--
--
Mr. Mark E. Spring, CPA
Mr. Mark E. Spring, CPA
Chief Financial Officer, Treasurer, Principal Financial Officer, Principal Accounting Officer
Chief Financial Officer, Treasurer, Principal Financial Officer, Principal Accounting Officer
--
--
Name
Name/Position
Position
Shareholding
Change
Ms. Connie L. Matsui
Ms. Connie L. Matsui
Independent Chairperson of the Board
Independent Chairperson of the Board
11.74K
+98.21%
Mr. Gregory D. (Greg) Gorgas
Mr. Gregory D. (Greg) Gorgas
President, Chief Executive Officer, Secretary, Director
President, Chief Executive Officer, Secretary, Director
4.02K
+71.71%
Mr. Steven (Steve) Kelly
Mr. Steven (Steve) Kelly
Independent Director
Independent Director
47.00
--
Dr. Douglas Blayney, M.D.
Dr. Douglas Blayney, M.D.
Independent Director
Independent Director
--
--
Dr. R. Martin Emanuele, Ph.D.
Dr. R. Martin Emanuele, Ph.D.
Independent Director
Independent Director
--
--
Dr. Gregory R. Reyes, M.D., Ph.D.
Dr. Gregory R. Reyes, M.D., Ph.D.
Independent Director
Independent Director
--
--
Revenue Breakdown
Relevant data have not been disclosed by the company yet.
Relevant data have not been disclosed by the company yet.
By Business
By Region
Relevant data have not been disclosed by the company yet.
Shareholding Stats
Updated: Thu, May 14
Updated: Thu, May 14
Shareholders
Shareholder Types
Shareholders
Shareholders
Proportion
Intracoastal Capital, L.L.C.
8.63%
Kathmere Capital Management
1.41%
Jane Street Capital, L.L.C.
1.39%
Matsui (Connie L)
1.25%
Vanguard Capital Management, LLC
1.08%
Other
86.23%
Shareholders
Shareholders
Proportion
Intracoastal Capital, L.L.C.
8.63%
Kathmere Capital Management
1.41%
Jane Street Capital, L.L.C.
1.39%
Matsui (Connie L)
1.25%
Vanguard Capital Management, LLC
1.08%
Other
86.23%
Shareholder Types
Shareholders
Proportion
Corporation
8.63%
Investment Advisor
3.33%
Individual Investor
2.10%
Hedge Fund
0.80%
Research Firm
0.60%
Investment Advisor/Hedge Fund
0.41%
Other
84.14%
Institutional Shareholding
Updated: Wed, Apr 1
Updated: Wed, Apr 1
Reporting Period
No. of institutions
Shares Held
Proportion
Change
2026Q1
21
34.88K
3.72%
+10.33K
2025Q4
17
33.04K
1.41%
--
2025Q3
20
33.04K
2.15%
+11.84K
2025Q2
19
16.59K
3.27%
+2.16K
2025Q1
19
14.43K
2.63%
+32.00
2024Q4
19
5.75K
4.25%
+1.99K
2024Q3
20
3.76K
4.35%
-524.00
2024Q2
28
4.29K
5.29%
+147.00
2024Q1
27
4.14K
5.67%
-26.34K
2023Q4
34
4.28K
6.32%
-4.63K
View more
Shareholder Activity
Name
Shares Held
Proportion
Change
Chg %
Date
Matsui (Connie L)
210.00
0.03%
-11.53K
-98.21%
Mar 23, 2026
Two Sigma Investments, LP
6.89K
0.87%
+6.89K
--
Dec 31, 2025
Virtu Americas LLC
5.62K
0.71%
+5.62K
--
Dec 31, 2025
Gorgas (Gregory D)
1.14K
0.14%
-2.88K
-71.70%
Mar 23, 2026
Geode Capital Management, L.L.C.
3.80K
0.48%
+3.80K
--
Dec 31, 2025
View more
Related ETFs
Name
Proportion
No Data
Dividend
A total of
0.00
USD has been distributed in dividends over the past 5 years.
Date
Dividend
Record Date
Payment Date
Ex-dividend Date
No Data
Stock Splits
Date
Ex-dividend Date
Type
Ratio
Mar 06, 2026
Merger
3→1
Jun 11, 2025
Merger
6→1
Aug 09, 2022
Merger
15→1
Aug 09, 2022
Merger
15→1
Aug 09, 2022
Merger
15→1
Aug 09, 2022
Merger
15→1
Date
Ex-dividend Date
Type
Ratio
Mar 06, 2026
Merger
3→1
Jun 11, 2025
Merger
6→1
Aug 09, 2022
Merger
15→1
Aug 09, 2022
Merger
15→1
Aug 09, 2022
Merger
15→1
Aug 09, 2022
Merger
15→1
